MiMedx Group (NASDAQ:MDXG) Stock Price Up 7% – Still a Buy?

Shares of MiMedx Group, Inc (NASDAQ:MDXG) rose 7% on Friday . The stock traded as high as $3.59 and last traded at $3.5950. Approximately 747,028 shares changed hands during mid-day trading, a decline of 38% from the average daily volume of 1,212,878 shares. The stock had previously closed at $3.36.

Analysts Set New Price Targets

MDXG has been the subject of several analyst reports. Cantor Fitzgerald cut their target price on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Wall Street Zen cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. UBS Group set a $10.00 price target on MiMedx Group in a report on Monday, February 23rd. Citizens Jmp lowered their price target on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday. Finally, Citigroup started coverage on MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Stock Up 8.8%

The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. The firm has a market cap of $543.02 million, a PE ratio of 18.13 and a beta of 1.65. The stock has a fifty day moving average price of $4.12 and a 200-day moving average price of $5.63.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.15% and a net margin of 7.88%.The business had revenue of $58.99 million during the quarter, compared to analysts’ expectations of $65.80 million. Research analysts expect that MiMedx Group, Inc will post 0.08 EPS for the current year.

Hedge Funds Weigh In On MiMedx Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC boosted its holdings in MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after acquiring an additional 1,725,458 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in MiMedx Group in the 3rd quarter worth approximately $1,759,000. SG Americas Securities LLC boosted its holdings in MiMedx Group by 419.3% in the 3rd quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock worth $1,130,000 after acquiring an additional 130,769 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in MiMedx Group by 433.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after acquiring an additional 234,958 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in MiMedx Group in the 3rd quarter worth approximately $54,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.